MedPath
HSA Approval

DUTABIT 0.5 SOFT CAPSULES 0.5MG

SIN16448P

DUTABIT 0.5 SOFT CAPSULES 0.5MG

DUTABIT 0.5 SOFT CAPSULES 0.5MG

March 22, 2022

APOTHECA MARKETING PTE LTD

APOTHECA MARKETING PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPOTHECA MARKETING PTE LTD
Licence HolderAPOTHECA MARKETING PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE, LIQUID FILLED

**Posology and method of administration** Posology Dutasteride can be administered alone or in combination with the alpha-blocker tamsulosin (0.4 mg) _**Adults (including elderly):**_ The recommended dose of Dutasteride is one capsule (0.5 mg) taken orally once a day. The capsules should be swallowed whole and not chewed or opened as contact with the capsule contents may result in irritation of the oropharyngeal mucosa. The capsules may be taken with or without food. Although an improvement may be observed at an early stage, it can take up to 6 months before a response to the treatment can be achieved. No dose adjustment is necessary in the elderly. _**Renal impairment**_ The effect of renal impairment on Dutasteride pharmacokinetics has not been studied. No adjustment in dosage is anticipated for patients with renal impairment _**Hepatic impairment**_ The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied so caution should be used in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the use of dutasteride is contraindicated.

ORAL

Medical Information

**Therapeutic indications** Treatment and control of benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce prostate size, reduce the risk of acute urinary retention, and reduce the need for BPH-related surgery. In addition, Dutasteride in combination with the alpha-blocker tamsulosin is indicated for the treatment of symptomatic BPH in men with an enlarged prostate.

**Contraindications** Dutasteride is contraindicated in: - Women, children and adolescents. - Patients with hypersensitivity to dutasteride, to other 5-alpha reductase inhibitors or any of the other excipients. - Patients with severe hepatic impairment.

G04CB02

dutasteride

Manufacturer Information

APOTHECA MARKETING PTE LTD

AUROBINDO PHARMA LIMITED - UNIT VII

Active Ingredients

Dutasteride

0.5mg

Dutasteride

Documents

Package Inserts

Dutabit 0.5 Soft Capsules PI.pdf

Approved: January 11, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DUTABIT 0.5 SOFT CAPSULES 0.5MG - HSA Approval | MedPath